Eloralintide for Kidney Disease

Recruiting at 1 trial location

Overseen By Physicians interested in becoming principal investigators please contact

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Eli Lilly and Company

Must not be taking: Dialysis drugs

Disqualifiers: Chronic liver disease, Organ transplant, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 1 day

28 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin).

For each participant, the study will last about 14 weeks, excluding screening.

Who Is on the Research Team?

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Are You a Good Fit for This Trial?

Inclusion Criteria

My blood pressure and pulse rate are within a healthy range.

* Have no significant history of spontaneous or ethanol-induced hypoglycemia

My weight is at least 55 kg and my BMI is between 19.0 and 40.0.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single dose of Eloralintide administered subcutaneously

1 day

Follow-up

Participants are monitored for pharmacokinetics and safety over the study period

14 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Eloralintide (LY3841136)

How Is the Trial Designed?

Group I: Eloralintide (Groups 2 and 3) Experimental Treatment 1 Intervention

Eloralintide administered SC in groups of participants with impaired renal function

Group II: Eloralintide (Group 3) Experimental Treatment 1 Intervention

Eloralintide administered SC in a group of participants with end-stage renal disease (ESRD) on stable hemodialysis

Group III: Eloralintide (Group 1) Experimental Treatment 1 Intervention

Eloralintide administered subcutaneously (SC) in a control group of participants with normal renal function

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University